The World Health Organization has issued its first guidelines for the use of GLP-1 drugs, including their use in treating obesity. The guidelines appear to address the use of these medications in various health contexts, although the scope and details of the guidelines are not entirely clear. It is reported that the WHO considers GLP-1 drugs a significant development, but the full implications and recommendations of the guidelines are not uniformly specified across reports.